CA-DEGREED
15.6.2022 14:06:09 CEST | Business Wire | Press release
Degreed, a pioneer in learning experience for eight million users, today shared the results of a commissioned Total Economic ImpactTM (TEI) study of its Learning Experience Platform (LXP). The study, conducted by Forrester Consulting found that organizations using Degreed’s LXP experienced faster time-to-productivity for new employees, democratization of learning across the workforce, improved upskilling, and lower learning content costs. The potential total return-on-investment calculated in the study was 312%, with a net present value (NPV) of $4.69M and payback in under six months. Read the full study here .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615005110/en/
“Our customers choose Degreed alongside their LMSs and HCM systems to build the skills their people need faster and more efficiently. We believe this Total Economic ImpactTM study highlights how Degreed’s more open, collaborative learning experience can create value at every stage of the employee lifecycle — from faster new hire onboarding to more efficient upskilling and lower turnover in key roles, not to mention reduced content spend and higher productivity for L&D teams,” said Todd Tauber, SVP Strategy at Degreed.
The study found organizations using Degreed had a 20% faster time-to-productivity for new employees due to a more consistent onboarding process, centered around high quality content and easily navigated learning pathways.
According to the study, “Interviewees’ organizations used Degreed to upskill employees and improve their organizations’ performance in a number of areas, including customer satisfaction and retention, data storage and analysis, product support, diversity and inclusion, leadership and management, and technology changes.”
One professional services organization was able to make onboarding more relevant and timely for new starters, where previously it depended on live instructors at synchronous training sessions, which delayed onboarding timelines and made the experience inconsistent.
Another customer commented on the benefits of the LXP’s open ecosystem, stating, “Degreed is the primary learning interface for us and it caters to the diverse needs of our employees, as well as our organization. With Degreed, we've achieved targeted and business-focused skill development.”
The improved upskilling of current employees across all respondents was 35% for employees and 25% for trainers because of the single gateway for all learning that Degreed provides. The study additionally found that Degreed led to better retention in key roles, decreasing from 10% to 2%, particularly in leadership positions and those who regularly deal with new challenges.
There were additional unquantified benefits that were identified by the study including bringing a social, consumer-grade learning experience to corporate learning, leading to higher levels of engagement, and the democratization of learning, particularly for frontline workers, those in new regions, and employees speaking different languages.
Interviewees also said that Degreed was one of their organization’s core technologies that provided the agility needed to successfully operate through remote work.
To read the full study, click here .
Degreed is hosting a webinar featuring Forrester to dive further into the details of the study, click here to register .
Editor’s notes
TEI Framework And Methodology
From the information provided in the interviews, Forrester constructed a Total Economic ImpactTM framework for those organizations considering an investment in Degreed.
The objective of the framework is to identify the cost, benefit, flexibility, and risk factors that affect the investment decision. Forrester took a multistep approach to evaluate the impact that Degreed can have on an organization.
About Degreed
Degreed empowers growth and innovation through lifelong learning. As a changemaker on a global scale, we serve more than 100 of the Global 2000 and one in three Fortune 50 companies, sparking a culture of learning across the enterprise. In one fluid experience, we help you identify the skills you have and build the skills you need—through individual, collaborative and experiential modes of learning—to drive personal career growth and business results. Founded in 2012, Degreed is translated into 28 languages with users spanning more than 200 countries.
Learn more about Degreed: Website | YouTube | LinkedIn | Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20220615005110/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
